Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Predictors of elevated tumour necrosis factor α level in obstructive sleep apnoea syndrome

Silke Ryan, CormacT. Taylor, WalterT. McNicholas
European Respiratory Review 2006 15: 221-223; DOI: 10.1183/09059180.00010127
Silke Ryan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CormacT. Taylor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WalterT. McNicholas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Circulating levels of TNF-α are elevated in Obstructive Sleep Apnoea Syndrome (OSAS) and likely contribute to associated cardiovascular diseases. Furthermore, TNF-α has been suggested as a mediator of excessive daytime sleepiness (EDS). We investigated the predictors of TNF-α in OSAS in large, well-selected patient and control cohorts.

We undertook a prospective study of 30 non-OSAS (including 22 non-sleepy controls and 8 sleepy non-apnoeic snorers), 36 mild-moderate OSAS and 31 severe OSAS male subjects. All groups were closely matched in age, BMI, smoking status, blood pressure and lipid profile. All subjects were free of other disease and were not taking regular medication. Serum for TNF-α assay was drawn following polysomnography (PSG) in all subjects. 49 patients were commenced on CPAP therapy within one week following PSG; sleep studies and TNF-α measurements were repeated 6 weeks later.

TNF-α was higher in OSAS patients than controls (p<0.001). In multivariate analysis, TNF-α was independently associated with the desaturation index (r = 0.399, p<0.001), the Epworth Sleepiness Score (ESS) (r = 0.243, p = 0.005) and total cholesterol (r = 0.216, p = 0.018). Furthermore, levels were higher in sleepy non-OSAS patients than in controls (4.49[3.35,6.94] pg·ml−1 vs 2.46[1.66,3.40]; p = 0.002) but lower than in severe OSAS patients (6.32[5.70,8.17]; p = 0.03). CPAP significantly lowered TNF-α (from 5.56±2.10 to 4.13±2.99 pg·ml−1; p = 0.004).

The severity of intermittent hypoxia is the strongest predictor of TNF-α level supporting a key role of inflammation in the cardiovascular pathophysiology of OSAS. Furthermore, TNF-α is independently associated with EDS.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

MY JOB AND THE UNIT IN WHICH I WORK

I am a Specialist Registrar in Respiratory Medicine and have spent the last 3 yrs in full-time research to complete a PhD thesis. The work, as presented in my abstract, has been the product of an ongoing intense and exciting collaboration between the Sleep Disorders Unit at St. Vincent's University Hospital (Dublin, Ireland), under the directorship of Prof. Walter McNicholas, Past President of the European Respiratory Society, and the hypoxia research group led by Prof. Cormac Taylor in the Conway Institute at University College Dublin (Dublin). The Sleep Laboratory at St. Vincent's Hospital is the largest unit in the country dealing with sleep-related breathing disorders. We mainly see patients suffering from obstructive sleep apnoea syndrome (OSAS) and we perform ∼250 diagnostic sleep studies per year. In addition, we spend a great deal of time initiating and supervising treatment with continuous positive airway pressure (CPAP) therapy. Furthermore, the laboratory has great expertise in the management of breathing disorders related to various respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. The Conway Institute at University College Dublin is an institution with state-of-the-art facilities targeted towards biomedical and biomolecular research. The research group led by Prof. Cormac Taylor has an international reputation in investigating cell and molecular mechanisms of hypoxia. The combination of the established clinical and physiological research strengths of the Sleep Research Laboratory and the extensive research record of Prof. Taylor's group in the cellular and molecular responses to hypoxia allows us to implement a programme of translational research. This research is directed towards a better understanding of the consequences for disorders associated with chronic intermittent hypoxia, such as OSAS.

MY WINNING ABSTRACT AS PART OF MY RESEARCH

My PhD, which I started in July 2003, is entitled “Activation of inflammatory pathways by intermittent hypoxia and its role in the cardiovascular pathophysiology of obstructive sleep apnoea syndrome”. OSAS is a highly prevalent disorder affecting ∼4% of males and 2% of females [1], and with the growing incidence of obesity worldwide the prevalence of OSAS is also steadily growing. The predominant morbidity of OSAS is cardiovascular and OSAS is an independent risk factor for cardiovascular diseases, particularly systemic arterial hypertension but also coronary artery disease, congestive cardiac failure and cerebrovascular accidents [2–4]. The mechanisms by which OSAS predispose to cardiovascular disease remain unclear. The pathogenesis is most likely multifactorial and potential mechanisms include sympathetic excitation, inflammation, vascular endothelial dysfunction and metabolic dysregulation [5]. However, it is likely that for OSAS the typical cyclical pattern of intermittent hypoxia and re-oxygenation plays a significant role in the pathophysiology. In particular, the intermittent re-oxygenation that distinguishes intermittent from sustained hypoxia resembles reperfusion injury and may result in the development of atherosclerosis. While the detailed molecular mechanisms underlying the cellular response to intermittent hypoxia remain unknown, the cellular responses to sustained hypoxia are well described and characterised by alteration in the expression of a number of adaptive genes, including stress-related genes and corresponding proteins that are necessary to maintain homeostasis [6]. Cells have developed protective transcriptional strategies in order to respond to sustained hypoxia. The master regulator in sensing hypoxic conditions and in integrating an adaptive response via gene expression is the transcription factor hypoxia-inducible factor-1 (HIF-1). HIF-1 activates transcription of genes encoding proteins that will either increase oxygen delivery (e.g. vascular endothelial growth factor, erythropoietin, endothelin-1) or achieve metabolic adaptations under conditions of reduced oxygen availability (e.g. glucose transporter-1 and glycolytic enzymes). Such factors mediate an adaptive response to hypoxia directed towards increasing tissue perfusion and oxygenation, and hence overcoming the initial hypoxic insult [7].

Sustained hypoxia also leads to the activation of other transcription factors, such as nuclear factor (NF)-κB [8]. NF-κB plays a central role in various physiological and pathophysiological processes. It is the key transcription factor in the inflammatory response and activated NF-κB controls the expression of many genes, including those encoding inflammatory cytokines, such as tumour necrosis factor (TNF)-α and interleukin (IL)-6, chemokines such as IL-8, adhesion molecules such as intercellular adhesion molecule-1 and cell receptors [9]. These mediators have also been linked to the pathogenesis of atherosclerosis and hypertension [10]. A number of reports have shown an increase of circulating levels of these markers in OSAS and a significant fall with effective CPAP therapy [11–13].

We have developed a novel in vitro model of intermittent hypoxia and generated data indicating that intermittent hypoxia leads to a selective dose-dependent activation of pro-inflammatory events mediated by NF-κB without significant activation of the protective HIF-1-dependent pathway [14]. These findings demonstrate that the intermittent hypoxia associated with OSAS may selectively activate molecular pathways that are pro-atherogenic; in this way the cellular response to intermittent hypoxia differs greatly from the response to sustained hypoxia.

At the 2006 European Respiratory Society Annual Congress, we presented data translating the findings of our cell culture model into the clinical picture of OSAS; in a large prospective study, we have demonstrated a significant relationship between NF-κB-dependent genes, TNF-α and IL-8, and sleep-related oxygen desaturation occurring in OSAS patients [15]. Furthermore, we have demonstrated that CPAP therapy is an effective treatment for lowering this inflammatory response.

These results support our central hypothesis of a selective activation of the transcription factor NF-κB by OSAS leading to an inflammatory response that may contribute to the development of cardiovascular complications in this disorder. Furthermore, the data support a key role of TNF-α and IL-8 as cardiovascular risk markers in OSAS.

THE IMPACT OF MY WORK ON CLINICAL OR RESEARCH PRACTICE

In conclusion, the present data provide evidence for a specific role of intermittent hypoxia in inflammatory processes contributing to cardiovascular complications in OSAS. Further research is required to understand the detailed signalling mechanisms of NF-κB activation by OSAS and to explore the detailed molecular consequences of this event.

    • © ERSJ Ltd

    References

    1. ↵
      Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328: 1230–1235.
      OpenUrlCrossRefPubMed
    2. ↵
      Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283: 1829–1836.
      OpenUrlCrossRefPubMed
    3. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163: 19–25.
      OpenUrlCrossRefPubMed
    4. ↵
      Young T, Peppard P. Sleep-disordered breathing and cardiovascular disease: epidemiologic evidence for a relationship. Sleep 2000; 23: Suppl. 4 S122–S126.
      OpenUrlPubMed
    5. ↵
      McNicholas WT, Ryan S. Obstructive sleep apnoea syndrome: translating science to clinical practice. Respirology 2006; 11: 136–144.
      OpenUrlCrossRefPubMed
    6. ↵
      Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 1996; 76: 839–885.
      OpenUrlAbstract/FREE Full Text
    7. ↵
      Semenza GL. O2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. J Appl Physiol 2004; 96: 1173–1177.
      OpenUrlAbstract/FREE Full Text
    8. ↵
      Cummins EP, Taylor CT. Hypoxia-responsive transcription factors. Pflugers Arch 2005; 450: 363–371.
      OpenUrlCrossRefPubMed
    9. ↵
      Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280–288.
      OpenUrlCrossRefPubMed
    10. ↵
      Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109 21: Suppl. 1 II2–II10.
    11. ↵
      Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107: 1129–1134.
      OpenUrlAbstract/FREE Full Text
    12. Ohga E, Tomita T, Wada H, Yamamoto H, Nagase T, Ouchi Y. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol 2003; 94: 179–184.
      OpenUrlAbstract/FREE Full Text
    13. ↵
      Minoguchi K, Tazaki T, Yokoe T, et al. Elevated production of tumor necrosis factor-α by monocytes in patients with obstructive sleep apnea syndrome. Chest 2004; 126: 1473–1479.
      OpenUrlCrossRefPubMed
    14. ↵
      Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112: 2660–2667.
      OpenUrlAbstract/FREE Full Text
    15. ↵
      Ryan S, Taylor CT, McNicholas WT. Predictors of elevated nuclear factor κB-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2006; 174: 824–830.
      OpenUrlCrossRefPubMed
    PreviousNext
    Back to top
    View this article with LENS
    Vol 15 Issue 101 Table of Contents
    European Respiratory Review: 15 (101)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Predictors of elevated tumour necrosis factor α level in obstructive sleep apnoea syndrome
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Predictors of elevated tumour necrosis factor α level in obstructive sleep apnoea syndrome
    Silke Ryan, CormacT. Taylor, WalterT. McNicholas
    European Respiratory Review Dec 2006, 15 (101) 221-223; DOI: 10.1183/09059180.00010127

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Predictors of elevated tumour necrosis factor α level in obstructive sleep apnoea syndrome
    Silke Ryan, CormacT. Taylor, WalterT. McNicholas
    European Respiratory Review Dec 2006, 15 (101) 221-223; DOI: 10.1183/09059180.00010127
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Abstract
      • MY JOB AND THE UNIT IN WHICH I WORK
      • MY WINNING ABSTRACT AS PART OF MY RESEARCH
      • THE IMPACT OF MY WORK ON CLINICAL OR RESEARCH PRACTICE
      • References
    • Figures & Data
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Smoking and impact on health
    • Nonpharmacological smoking cessation interventions in clinical practice
    • Pharmacological treatments for tobacco dependence
    Show more Original Articles

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERR

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising
    • Sponsorship

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN: 0905-9180
    Online ISSN: 1600-0617

    Copyright © 2022 by the European Respiratory Society